You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic non-small cell lung cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Guangzhou (BL-M07D1)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 1, 2023

Elderly Patients, Metastatic Lung Cancer Trial in Wuhan (Single drug chemo plus immunotherapy)

Not yet recruiting
  • Elderly Patients
  • Metastatic Lung Cancer
  • Single drug chemotherapy plus immunotherapy
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Sep 15, 2023

NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Tislelizumab IV
  • +2 more
  • (no location specified)
Oct 25, 2023

Non-Small-Cell Lung Cancer Trial in Guangzhou (PLB1004)

Recruiting
  • Non-Small-Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong General Hospital
Aug 25, 2023

Locally Advanced or Metastatic NSCLC Trial (Utidelone Injection, Docetaxel Injection)

Not yet recruiting
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • Utidelone Injection
  • Docetaxel Injection
  • (no location specified)
Dec 30, 2022

Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Oslo, Norway
    Pfizer Norway
Apr 17, 2023

NSCLC Trial in Shanghai (SI-B001, SI-B003)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Jul 10, 2023

Locally Advanced or Metastatic NSCLC Trial (HB1801, Taxotere)

Not yet recruiting
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • (no location specified)
May 8, 2023

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

NSCLC Trial in Shanghai (BL-M02D1)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Jul 10, 2023

Lung Cancer Stage IV Trial in Kaunas (Bronchoscopic cryotherapy, Pembrolizumab, Platinum based chemo)

Recruiting
  • Lung Cancer Stage IV
  • Bronchoscopic cryotherapy
  • +2 more
  • Kaunas, Lithuania
    Lithuanian University of Health Sciences
Aug 16, 2023

NSCLC Trial in Seoul (Lazertinib/Pemetrexed/Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Mar 23, 2023

NSCLC Trial in Guangzhou (SKB264, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University, Cancer Center
Apr 14, 2023

Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer Trial (Pembrolizumab, GT103)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Jan 12, 2023

Metastatic Non Small Cell Lung Cancer Trial in Raleigh (C-TIL051)

Not yet recruiting
  • Metastatic Non Small Cell Lung Cancer
  • C-TIL051
  • Raleigh, North Carolina
    Duke Cancer Institute
Jan 6, 2023

NSCLC Trial (Tirelizumab;Chemotherapy monotherapy)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Tirelizumab；Chemotherapy monotherapy
  • (no location specified)
Jul 27, 2023

Colorectal Cancer, NSCLC Trial (GDC-1971, Osimertinib, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • (no location specified)
Jul 12, 2023

Non Small Cell Lung Cancer Trial (Navtemadlin, Navtemadlin Placebo, Pembrolizumab)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • (no location specified)
Jan 27, 2023

NSCLC Trial in Korea, Republic of, Malaysia, United States (Cetrelimab, Amivantamab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Fairfax, Virginia
  • +3 more
Jun 16, 2023

Metastatic NSCLC Trial (Pembrolizumab coformulated with hyaluronidase, Pemetrexed, Cisplatin)

Not yet recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Pembrolizumab coformulated with hyaluronidase
  • +6 more
  • (no location specified)
Jan 27, 2023

NSCLC, NSCLC, PD-1 Trial in Beijing (F520, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Feb 22, 2023

NSCLC Trial in Busan (GDC-6036, Pembrolizumab)

Recruiting
  • Non-Small Cell Lung Cancer
  • Busan, Korea, Republic of
    Pusan National University Hospital
Apr 3, 2023

NSCLC Metastatic Trial in La Jolla (Nivolumab + Plinabulin)

Active, not recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Nivolumab + Plinabulin
  • La Jolla, California
    UC San Diego Moores Cancer Center
Nov 21, 2022

Metastatic NSCLC, Metastatic Triple-negative Breast Cancer Trial in Houston (biological, drug, radiation)

Active, not recruiting
Has Results
  • Metastatic Non-small Cell Lung Cancer
  • Metastatic Triple-negative Breast Cancer
  • ADV/HSV-tk
  • +3 more
  • Houston, Texas
    Houston Methodist Cancer Center
Dec 28, 2022

NSCLC Trial (KB-GDT-01)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • KB-GDT-01
  • (no location specified)
Sep 29, 2023